The Phase III EPIK‐O trial evaluating the PI3K alpha blocker alpelisib and olaparib in high‐grade serous ovarian cancer patients without germline BRCA mutations has recently completed enrollment and it will be intriguing to see if this trial has more success with single agent blockade of the PI3K/AKT/mTOR pathway. This evidence concerns the gene AKT1 and ovarian serous adenocarcinoma.